Deciding between biobetter versus biosimilar development options based on net present value calculations

 

Abstract

The growing share of biopharmaceuticals is paralleled by an increasing interest in biogenerics, as blockbuster biologics are approaching their patent expiries. Companies need to make decisions whether to invest in biosimilars or in biobetters with enhanced properties, the latter enabling favorable differentiation vis-à-vis the original product on the one hand and biosimilars on the other hand. Net present value (NPV) modelling was applied to evaluate the financial attractiveness of two categories of biobetters in comparison to biosimilars, and recommendations are made which options should be preferred depending on a company’s business model.


Canadian Venture Capital – Unlocking the Funding Challenge

Canada plays a significant role in the global advancement of scientific discoveries and their translation into commercial opportunities, but is viewed as not fully realizing its commercial potential. A significant problem has been a lack of sufficient venture capital to take early-stage companies to the next level. Several recent developments may signal the arrival of a more positive venture-funding environment for life sciences and health technology enterprises, including the development of the Canadian government’s C$400 million Venture Capital Action Plan; pharmaceutical companies electing to establish or investing in venture funds and providing strategic support to early-stage ventures, including through the creation of research centres; and recent successful liquidity events for venture investors.


Pharmaceutical R&D Productivity: The Role of Alliance

In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and d…


Building biotechnology in India – Drugs are not the answer

Ihave had the pleasure of participating in national forums on biotechnology development in diverse countries. A common theme I see is that emerging economies wish to develop ‘a biotechnology industry like the United States.’ I generally temper these ambitions by explaining that the United States does not have a biotechnology industry per se, but rather a handful of states have very strong biotechnology concentrations and many other states are still trying to build their domestic biotechnology industries. So the lesson for many emerging economies is to set ambitions at the US-state level rather than the US-national level. Furthermore, I also caution against aiming for drug development. Drug development is extremely expensive and risky—focusing on domestic agricultural or industrial biotechnology opportunities may be a better option.


Fostering technology transfer in industrial biotechnology by academic spin-offs

Industrial biotechnology is the commercial application of biotechnology using cells or components of cells, like enzymes, for industrial production processes including consumer goods, bioenergy and biomaterials. In the last years this area has gone thr…


Why pharma's 'anti-competitive' practices may actually be good

The FTC is reportedly seeking $1 billion from pharmaceutical companies for the role in paying generic companies not to challenge their patents. Despite first appearances, these agreements for a generic company not to challenge a patent, called ‘reverse settlements’, may actually be good for innovation. The rationale for reverse settlements is discussed in my textbook, […]


Drug Patent Expirations for March 18 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for March 18 2014

TradenameApplicantGeneric NamePatent
Expiration

ACCOLATE

Astrazeneca

zafirlukast

Mar 18, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape
Go to paperABSTRACT: Patent analytical da…


Scientific American Discusses 2014 Worldview Global Biotechnology Innovation Assessment

For those who missed the live presentation, here is the discussion of the 2014 Scientific American Worldview scorecard, featuring myself, Mike May (Worldview Editorial Director), David Brancaccio ( public radio’s Marketplace), and Caroline Rugierri (Access Life Sciences). Some of the themes we discussed were: Innovation’s true “value proposition” and the ways in which investing in science has multilayered […]


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: